WO2005113813A8 - Nucleic acid ligands specific to immunoglobulin e and their use as atopic disease therapeutics - Google Patents

Nucleic acid ligands specific to immunoglobulin e and their use as atopic disease therapeutics

Info

Publication number
WO2005113813A8
WO2005113813A8 PCT/US2005/014361 US2005014361W WO2005113813A8 WO 2005113813 A8 WO2005113813 A8 WO 2005113813A8 US 2005014361 W US2005014361 W US 2005014361W WO 2005113813 A8 WO2005113813 A8 WO 2005113813A8
Authority
WO
WIPO (PCT)
Prior art keywords
immunoglobulin
nucleic acid
atopic disease
acid ligands
ligands specific
Prior art date
Application number
PCT/US2005/014361
Other languages
French (fr)
Other versions
WO2005113813A2 (en
WO2005113813A3 (en
Inventor
Sharon Cload
John L Diener
Sara Chesworth Keene
Markus Kurz
H A Daniel Lagasse
Harold Nicholas Marsh
Pooja Sawhney
Original Assignee
Archemix Corp
Sharon Cload
John L Diener
Sara Chesworth Keene
Markus Kurz
H A Daniel Lagasse
Harold Nicholas Marsh
Pooja Sawhney
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Archemix Corp, Sharon Cload, John L Diener, Sara Chesworth Keene, Markus Kurz, H A Daniel Lagasse, Harold Nicholas Marsh, Pooja Sawhney filed Critical Archemix Corp
Priority to CA002564311A priority Critical patent/CA2564311A1/en
Priority to AU2005245793A priority patent/AU2005245793A1/en
Priority to EP05779587A priority patent/EP1742959A2/en
Priority to JP2007510909A priority patent/JP2007534339A/en
Publication of WO2005113813A2 publication Critical patent/WO2005113813A2/en
Publication of WO2005113813A8 publication Critical patent/WO2005113813A8/en
Publication of WO2005113813A3 publication Critical patent/WO2005113813A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/331—Universal or degenerate base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate

Abstract

The invention discloses aptamers capable of binding to Immunoglobulin E (“IgE”) useful as therapeutics in and diagnostics of atopic disease and/or other diseases or disorders in which IgE has been implicated. The invention further relates to materials and methods for the administration of aptamers capable of binding to IgE.
PCT/US2005/014361 2004-04-26 2005-04-26 Nucleic acid ligands specific to immunoglobulin e and their use as atopic disease therapeutics WO2005113813A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002564311A CA2564311A1 (en) 2004-04-26 2005-04-26 Nucleic acid ligands specific to immunoglobulin e and their use as atopic disease therapeutics
AU2005245793A AU2005245793A1 (en) 2004-04-26 2005-04-26 Nucleic acid ligands specific to immunoglobulin e and their use as atopic disease therapeutics
EP05779587A EP1742959A2 (en) 2004-04-26 2005-04-26 Nucleic acid ligands to immunoglobulin e and their use as atopic disease therapeutics
JP2007510909A JP2007534339A (en) 2004-04-26 2005-04-26 Nucleic acid ligands specific for immunoglobulin E and their use as atopic disease treatment

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US56560104P 2004-04-26 2004-04-26
US60/565,601 2004-04-26
US57412004P 2004-05-24 2004-05-24
US60/574,120 2004-05-24
US58186504P 2004-06-22 2004-06-22
US60/581,865 2004-06-22
US66020405P 2005-03-07 2005-03-07
US60/660,204 2005-03-07

Publications (3)

Publication Number Publication Date
WO2005113813A2 WO2005113813A2 (en) 2005-12-01
WO2005113813A8 true WO2005113813A8 (en) 2006-03-09
WO2005113813A3 WO2005113813A3 (en) 2006-08-24

Family

ID=35428939

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/014361 WO2005113813A2 (en) 2004-04-26 2005-04-26 Nucleic acid ligands specific to immunoglobulin e and their use as atopic disease therapeutics

Country Status (6)

Country Link
EP (1) EP1742959A2 (en)
JP (1) JP2007534339A (en)
KR (1) KR20070044813A (en)
AU (1) AU2005245793A1 (en)
CA (1) CA2564311A1 (en)
WO (1) WO2005113813A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5135578B2 (en) * 2007-02-20 2013-02-06 国立大学法人金沢大学 Magnetic resonance measuring apparatus, integrated circuit, and magnetic resonance measuring method
CN103649741B (en) 2011-07-04 2016-11-16 日本电气方案创新株式会社 Evaluate the method for the redox active of nucleic acid molecules and there is the nucleic acid molecules of redox active
KR102213609B1 (en) 2012-07-13 2021-02-08 웨이브 라이프 사이언시스 리미티드 Chiral control

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629155A (en) * 1990-06-11 1997-05-13 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to immunoglobulin E (IgE)
US5766853A (en) * 1990-06-11 1998-06-16 Nexstar Pharmaceuticals, Inc. Method for identification of high affinity nucleic acid ligands to selectins
CA2329252A1 (en) * 1998-05-21 1999-11-25 Isis Pharmaceuticals Inc. Compositions and methods for topical delivery of oligonucleotides
WO2003102212A2 (en) * 2002-05-31 2003-12-11 Regents Of The University Of Minnesota In vitro evaluation of nucleic acid ligands
US20040022727A1 (en) * 2002-06-18 2004-02-05 Martin Stanton Aptamer-toxin molecules and methods for using same
EP1543158B1 (en) * 2002-07-25 2011-07-13 Archemix Corp. Regulated aptamer therapeutics
US9303262B2 (en) * 2002-09-17 2016-04-05 Archemix Llc Methods for identifying aptamer regulators

Also Published As

Publication number Publication date
WO2005113813A2 (en) 2005-12-01
KR20070044813A (en) 2007-04-30
WO2005113813A3 (en) 2006-08-24
EP1742959A2 (en) 2007-01-17
AU2005245793A2 (en) 2008-08-28
CA2564311A1 (en) 2005-12-01
AU2005245793A1 (en) 2005-12-01
JP2007534339A (en) 2007-11-29

Similar Documents

Publication Publication Date Title
WO2006033854A3 (en) Aptamers to von willebrand factor and their use as thrombotic disease therapeutics
WO2006029258A3 (en) Aptamer medicinal chemistry
WO2010033279A3 (en) Antibodies with altered binding to fcrn and methods of using same
WO2008116149A3 (en) Apoptotic anti- ige antibodies binding the membrane-bound ige
HK1222870A1 (en) Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r il-22 il-22r
RS20080075A (en) Aptamers that bind thrombin with high affinity
WO2008036341A3 (en) Compositions and methods relating to glucagon receptor antibodies
WO2006003388A8 (en) Compositions and methods for treating inflammatory disorders
WO2010017196A3 (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
WO2007098420A8 (en) Peptides that block the binding of igg to fcrn
WO2007045477A8 (en) Human antibodies against il-13 and therapeutic uses
WO2005100403A3 (en) Antibodies to erythropoietin receptor and uses thereof
WO2007113172A3 (en) Antibodies against amyloid-beta peptide
WO2007137984A3 (en) Modified humanised anti-interleukin-18 antibodies
WO2008024188A3 (en) Dual variable domain immunoglobulin and uses thereof
WO2007042573A3 (en) Compositions and methods for treating proliferative disorders
TW200740849A (en) Dual variable domain immunoglobulin and uses thereof
WO2008136848A3 (en) Novel anti-notch3 antibodies and their use in the detection and diagnosis of disease
WO2008008359A3 (en) Benzofuro-and benzothienopyryimidine modulators of the histamine h4 receptor
IL198379A (en) Humanized antibodies and antibody fragments that specifically bind sphingosine-1-phosphate, nucleic acids encoding the same and compositions and methods for use thereof to treat disease
WO2006096222A3 (en) Nucleic acid ligands specific to immunoglobulin e and their use as atopic disease therapeutics
WO2008099178A3 (en) Binding members for ige molecules
WO2008151819A3 (en) Treatment of tumors using specific anti-l1 antibody
WO2006135694A3 (en) Uii-modulating compounds and their use
WO2009140383A3 (en) Aptamers that bind to p-selectin and their use as coagulation, thrombotic, inflammatory, and metastatic disease therapeutics

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page

Free format text: UNDER (54) PUBLISHED TITLE REPLACED BY CORRECT TITLE

WWE Wipo information: entry into national phase

Ref document number: 2564311

Country of ref document: CA

Ref document number: 2007510909

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 6413/DELNP/2006

Country of ref document: IN

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2005245793

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005779587

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020067024878

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2005245793

Country of ref document: AU

Date of ref document: 20050426

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005245793

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200580021366.6

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005779587

Country of ref document: EP

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)